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Dermal DNA tattoo immunizationa b s t r a c t
The skin is an attractive site for vaccination due to its accessibility and presence of immune cells surveil-
ling this barrier. However, knowledge of antigen processing and presentation upon dermal vaccination is
sparse. In this study we determined antigen processing routes that lead to CD8+ T cell activation following
dermal DNA tattoo immunization, exploiting a model antigen that contains an immunoproteasome-
dependent epitope. In agreement with earlier reports, we found that DNA tattoo immunization of wild
type (WT) mice triggered vigorous responses to the immunoproteasome-dependent model epitope,
whereas gene-deficient mice lacking the immunoproteasome subunits b5i/LMP7 and b2i/MECL1 failed
to respond. Unexpectedly, dermal immunization both of irradiated bone marrow (BM) reconstituted mice
in which the BM transplant was of WT origin, and of WT mice transplanted with immunoproteasome
subunit-deficient BM induced a CD8+ T cell response to the immunoproteasome-dependent epitope,
implying that both BM and host-derived cells contributed to processing of delivered model antigen.
Depletion of radiation-resistant Langerhans cells (LC) from chimeric mice did not diminish tattoo-
immunization induced CD8+ T cell responses in most mice, illustrating that LC were not responsible
for antigen processing and CD8+ T cell priming in tattoo-immunized hosts. We conclude that both BM
and non-BM-derived cells contribute to processing and cross-presentation of antigens delivered by der-
mal DNA tattoo immunization.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The earliest successful vaccination against smallpox was
accomplished by cutaneous vaccination. Nowadays most vaccines
are administered intramuscularly, but the skin remains a very
attractive target for vaccination, because of its accessibility and
possibilities for lower antigen doses. Currently, a number of cuta-
neous delivery methods are being tested, including different types
of microneedles and tattoo immunization. While these methods
have been demonstrated to induce both humoral and cellular
responses, the underlying mechanisms contributing to cellular
immune activation have only partially been explored.Vaccination-induced priming of CD8+ T cell responses requires
the cross-presentation of intradermally delivered antigens by pro-
fessional antigen presenting cells (pAPC), to CD8+ T cells in the
draining lymph nodes. Different studies have defined a variety of
pAPC subsets as responsible for the interaction with vaccine
antigen-specific CD8+ T cells, including dendritic cells (DC) residing
in the lymph nodes, langerin+ dermal DC, and Langerhans cells
(LC), although LC may either have a stimulatory or inhibitory role
[1–4]. Moreover, while induced CD8+ T cell responses are primed
by either of these DC subsets, it remains unclear whether these
DC process the epitopes they present, or acquire them from other,
non-dendritic, cells.
The epitopes, presented on (p)APC to CD8+ T cells, are processed
mainly by proteasomes, which are multi-catalytic enzyme com-
plexes present in the cellular cytosol and nucleus. Proteasome’ cat-
alytic activity is displayed by three subunits, b1, b2 and b5, present
in the inner two b rings of the 20S proteasome catalytic core par-
ticle. Exposure of cells to inflammatory cytokines induces the
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and b5i/LMP7, which replace their constitutively expressed homo-
logues in newly assembled proteasomes, leading to the formation
of intermediate-type proteasomes and immunoproteasomes [5].
Depending on the presence of either the inducible subunits or their
constitutive homologues, proteasomes display different catalytic
pocket conformations and peptide transport dynamics [6], which
quantitatively alters the pool of peptides produced by proteasomes
[7–9].
In contrast to most cell types, pAPCs express the proteasome
immunosubunits continuously and contain relatively high quanti-
ties of immunoproteasomes. In previous studies using b2i/MECL1
and b5i/LMP7 double gene-deficient (b2i/MECL1-/-b5i/LMP7-/-) KO
mice [10], we showed that priming of CD8+ T cell responses specific
for an adenovirus model antigen-derived epitope, E1B192-200,
required immunoproteasome-mediated antigen processing. CD8+
T cell responses to a second epitope derived from this antigen,
E1A234-243, were unaffected by the absence of immunosubunit
expression in these mice. We decided to use this model system
to determine antigen processing and presentation routes that lead
to the priming of the CD8+ T cell response after dermal DNA tattoo
immunization [11]. Using BM chimeric mice, composed of WT -,
CD207-diptheria toxin receptor knock in (KI) – and b2i/MECL1/-
b5i/LMP7/ (KO) recipients, reconstituted with WT – or KO BM,
we show that both BM- and non-BM-derived cells contribute to
the processing of pAPC-presented, dermally delivered vaccine anti-
gen, and that radiation-resistant LC are not responsible for the
CD8+ T cell activation.2. Material and methods
2.1. DNA vaccine
To generate the E1 DNA vaccine, the sequences coding for the
Adenovirus early-1-region (E1) derived epitopes E1A234-243
(SGPSNTPPEI) and E1B192-200 (VNIRNCCYI), each flanked by their
natural flanking sequences (encoding 15 amino acids, both N-
and C-terminally) [10], were inserted into the pVAX1 vector (Invit-
rogen), 30 of and in frame with a tetanus toxin fragment C domain 1
(TTFC)-encoding region [12,13].2.2. Mice and dermal DNA tattoo immunization
For construction of chimeric mice, bone marrow was flushed
from the femurs of donor mice, depleted of mature B and T cells
by incubation with a mixture of 10 lg/mL anti-mouse CD4 (clone
GK1.5; made in house), CD8 (clone YTS-169; made in house),
CD3 (12A2 clone; made in house) and CD19 (clone ID3; made in
house), and subsequent incubation with guinea pig complement
4.5 lg/mL for 30 min (Invitrogen). Recipient mice were irradiated
with 9 Gy as a single dose from an X-ray irradiator and reconsti-
tuted with 107 BM cells. They were allowed to reconstitute for 6
weeks. C57BL/6 J mice were purchased from Charles River,
B6.129S2-CD207tm3(DTR/GFP)Mal/J from Jackson and B6.SJL mice and
b2i/MECL1/b5i/LMP7/ mice were bred in the animal facility
of Utrecht University. The efficacy of reconstitution in mixed bone
marrow chimeric mice was evaluated by staining splenocytes with
anti-mouse CD11c-APC (clone N418; Biolegend), MHC-II-PE (clone
M5/114.15.2; Biolegend), CD45.1-PerCPcy5.5 (clone A20; Biole-
gend) and CD45.2-FITC (clone 104; Biolegend) and percentages of
host-derived DC was measured by FACS (Supplementary Fig. 1).
All mice were immunized at day 0, 3 and 6 with 15 ll cDNA (2
lg/ll) in TE buffer with a 9-needle bar mounted on a tattoo rotary
device (Cheyenne) on 100 Hz, at 1 mm depth for 1 min [11]. Allanimal experiments were approved by the Animal Ethics Commit-
tee from Utrecht University (DEC 2013.II.07.084).
2.3. LC Depletion
Depletion of LC in bone marrow chimeric mice in which
B6.129S2-Cd207tm3(DTR/GFP)Mal/J mice had been reconstituted with
B6.SJL bone marrow or b2i/MECL1/b5i/LMP7/ BM, was per-
formed by i.p. injection of 7.5 ng/gr body weight diphtheria toxin
(Sigma) in PBS at day 2, 0 and 6. Efficiency of depletion was mea-
sured by FACS analysis at day 0 (Supplementary Fig. 3).
2.4. rLM-E1 Infection
Recombinant L. monocytogenes rLM-E1 was grown in brain-
heart infusion medium (BD Biosciences) supplemented with 250
lg/ml spectinomycin and harvested while in log phase. Mice were
inoculated i.v. in the tail vein with a sub-lethal dose of 5000 CFU in
100 ll PBS.
2.5. Analysis of specific CD8+ T cell responses
2.5.1. Intracellular cytokine staining (ICS)
Donor derived CD8+ T cell responses were quantified as
reported [8]. Briefly, 2.5  106 erythrocyte depleted splenocytes
were incubated with or without 1 lg/ml synthetic E1B192-200
VNIRNCCYI or E1A234-243 SGPSNTPPEI for 6 h at 37 C in RPMI
1640 medium supplemented with 10% FCS-HI (Lonza), 2 mM L-
glutamine, 30 lM 2-mercaptoethanol (Gibco), 10 lM monensin
(eBioscience) and penicillin/streptomycin. In case of splenocytes
from mice infected with rLM-E1, 50 lg/mL gentamycin (Gibco)
was added to the medium as well. Cells were stained with anti-
mouse CD45.1-PerCPcy5.5 (clone A20; Biolegend), CD45.2-FITC
(clone 104; Biolegend) and CD8-APC (clone 53–6.7; eBioscience)
in the presence of anti-mouse CD16/CD32 (clone 2.4G2; made in
house), fixed and stained with IFNc-PE (clone XMG1.2; eBio-
science) and analyzed on a FACS Canto II (BD Biosciences) using
FlowJo software (Tree Star).
2.5.2. IFNc ELISPOT
MAIP ELISPOT plates (Millipore) were coated with 2 lg/ml anti-
mouse IFNc (clone AN18; made in house) in PBS overnight at 4 C.
Wells were washed and blocked with RPMI 1640 medium (Life
Technologies) containing FCS HI (Lonza). 5  105 or 2.5  105 ery-
throcyte depleted splenocytes were plated with or without 1 lg/ml
synthetic peptide for 6 h in 1 ml FCS-HI and 2-mercaptoethanol
(Gibco) supplemented RPMI at 37 C. Plates were washed with
PBS plus 0.01% tween 20 (PBST), and IFNc was detected with
biotinylated anti-mouse IFNc (clone XMG1.2; BD), followed by
alkaline phosphatase-conjugated streptavidin (Jackson Immuno
Research Laboratories), in PBST supplemented with 2% BSA. The
assay was developed with the Vector blue substrate kit (Vector
Laboratories) and analyzed using an ELISPOT plate reader and
scanner (AELVIS).
2.5.3. Statistical analysis
To compare donor-derived responses to individual epitopes
between the different groups of mice, epitope specific responses
of every mouse were corrected for background IFNc level as mea-
sured in samples incubated without peptide, in both IFNc- ELISPOT
and IFNc ICS. Differences in CD8+ T cell responses detected by ICS
or ELISPOT in C57BL/6 (WT) or b2i/MECL1/b5i/LMP7/ mice
(KO) mice that were tattooed or infected, were tested for signifi-
cance using Students T test. The variance homogeneity was tested
using Levene’s test. A Two-Way ANOVA, corrected for multiple
comparisons using Tukey’s correction was used to test for differ-
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were considered significant.
3. Results
3.1. Both infection with rLM-E1 and dermal E1 cDNA tattoo
immunization elicit CD8+ T cell responses towards E1B192-200 in
immunoproteasome competent mice only
To determine which cells process the antigens that prime CD8+
T cell responses following dermal DNA tattoo immunization, a p/
DNA vaccine was constructed encoding the adenovirus-derived
E1B192-200 and E1A234-243 epitopes [14] in context of their natural
flanking sequences, and preceded by TTFC, to enhance the
immunogenicity of this construct [15]. Earlier studies using the
same E1 sequences expressed by recombinant Listeria monocytoge-
nes (rLM-E1) [10] showed that E1B192-200 elicits a vigorous CD8+ T
cell response in infected immunoproteasome competent wild type
(WT) mice but, due to inefficient proteasome-mediated processing,
fails to prime E1B192-200-specific CD8+ T cells in b2i/MECL1/b5i/
LMP7/ (KO) mice. E1A234-243 is less immunogenic but triggers
comparable responses in both mouse strains [10].
To test whether tattoo immunization with constructed DNA
vaccine primes E1-specific CD8+ T cells, WT and KO mice were
immunized three times, within six consecutive days (Fig. 1A).
Seven days after the last immunization, E1B192-200 and E1A234-
243-specific CD8+ T cells were quantified in the spleen (Fig. 1A)
using IFNc ICS (Fig. 1B). Consistent with our previous studies
[10], we found that all WT mice mounted vigorous CD8+ T cell
responses to E1B192-200, while KOmice failed to respond to this epi-
tope (Fig. 1C). Responses to the control epitope E1A234-243 wereFig. 1. E1 cDNA tattoo immunization only elicits E1B-specific CD8+ T cells in immunop
mice were immunized using E1 cDNA tattoo immunization at day 0, 3 and 6 and at day
lymphocytes were gated (R1). R1 was gated on CD8+ T cells (R2). In R2 the percentage of
cells in the spleen of immunoproteasome competent C57BL/6 (WT, filled circles) or i
immunized using E1 cDNA tattoo immunization, were measured by re-stimulation ex viv
an individual mouse, corrected for IFNc background level as measured in samples incu
representative of two independent experiments (n  5 animals per group), analyzed usisimilar in the two strains (Fig. 1C). Thus, similar to infection with
rLM-E1 [10], priming of E1B192-200 – specific CD8+ T cell responses
by dermal DNA tattoo immunization requires
immunoproteasome-mediated E1 antigen processing, while both
immuno - and constitutive proteasomes produce the E1A234-243
epitope with sufficient efficiency to prime a CD8+ T cell response.
3.2. In infection with rLM-E1 the presence of proteasome
immunosubunits in BM derived cells, and not the periphery, is
essential for the processing of E1B192-200
To determine whether the pathogen-derived CD8+ T cell epi-
topes, presented by pAPC in rLM-E1 infection, are generated solely
by BM-derived cells or whether also non-BM-derived cells con-
tribute to epitope generation, bone marrow (BM) chimeric mice
were created. To this end, WT and KO recipient mice were lethally
irradiated and then reconstituted with either WT or KO BM. Six
weeks later, mice were infected i.v. with a sub-lethal dose of
rLM-E1 (Fig. 2A). Quantification of E1-specific CD8+ T cells in the
spleen at day 8 post infection showed that all mice reconstituted
with WT BM responded to the E1B192-200 epitope, although
responses detected in KO recipients were significantly lower than
these in WT recipient mice (Fig. 2B). In contrast, we did not detect
any response to E1B192-200 in either WT or KO recipient mice,
reconstituted with KO BM (Fig. 2B). As expected, CD8+ T cell
responses to the immunoproteasome-independent E1A234-243 epi-
tope were detected in all mouse groups, including chimeric mice
reconstituted with KO BM. Since rLM-E1-infected chimeric mice
that expressed the proteasome immunosubunits in all cells except
BM-derived cells failed to respond to the immunoproteasome-
dependent E1B192-200 epitope while mice reconstituted with WTroteasome competent mice. (A) C57BL/6 (WT) and b2i/MECL1/b5i/LMP7/ (KO)
13 the splenocytes were harvested. (B) Gating strategy; in the total cell population,
IFNc+CD8+ T cells was measured. (C) Percentages of E1A or E1B-specific IFNc+CD8+ T
mmunoproteasome deficient b2i/MECL1/b5i/LMP7/ (KO, filled squares) mice,
o with peptides and detected by IFNc ICS and flow cytometry. Every dot represents
bated with medium, and means (bars) ± SEM per peptide are indicated. Data are
ng a students’ T test (* P < .05).
Fig. 2. Infection with rLM-E1 is dependent on immunoproteasome competent BM-derived cells. (A) C57BL/6 (WT) and b2i/MECL1/b5i/LMP7/ (KO) bone marrow chimeric
mice were infected with rLM-E1 at day 0 and at day 8 the splenocytes were harvested. (B) Percentages of E1A or E1B-specific CD8+IFNc+ T cells in the spleen of mixed
immunoproteasome competent C57BL/6 (WT) or immunoproteasome deficient b2i/MECL1/b5i/LMP7/ (KO) individual BM chimeric mice, infected with rLM-E1, were
measured by re-stimulation ex vivo with peptides and detection by IFNc ICS and flow cytometry. Four different chimeric mice were used; B6.SJL (WT) ? C57BL/6 (WT)
chimera’s (filled circles), b2i/MECL1/b5i/LMP7/ (KO)? B6.SJL (WT) chimera’s (filled squares), B6.SJL (WT)? b2i/MECL1/b5i/LMP7/ (KO) chimera’s (filled triangles)
and b2i/MECL1/b5i/LMP7/ (KO)? b2i/MECL1/b5i/LMP7/ (KO) chimera’s (filled diamonds). Every dot represents an individual mouse, corrected for IFNc background
level as measured in samples incubated with medium, and means (bars) ± SEM per peptide are indicated. Data are representative of one independent experiment (n = 4
animals per group), analyzed using a two-way ANOVA with Tukey’s corrections (* P < .05, ** P < .01, *** P < .001, **** P < .0001).
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play an essential role in processing of pAPC-presented epitopes
that prime the rLM-E1-specific CD8+ T cell response following
rLM-E1 infection.
3.3. In E1 cDNA tattoo immunization, the presence of proteasome
immunosubunits in both BM derived cells as well as the periphery is
essential for the processing of E1B192-200
To determine processing routes of antigens delivered by dermal
DNA tattoo immunization, WT and KO recipients reconstituted
with WT or KO BM were tattoo-immunized with E1-DNA. Six days
after the last immunization, E1-specific CD8+ T cell responses wereFig. 3. Dermal DNA immunization is dependent on immunoproteasomes in both BM- an
cells or numbers of IFNc+ cells in the spleen of immunoproteasome competent C57BL/6 (
chimeric mice, immunized using E1 cDNA tattoo immunization, were measured by re-st
(B) IFNc ELISPOT. (A and B) Four different chimeric mice were used; B6.SJL (WT)? C57
chimera’s (filled squares), B6.SJL (WT)? b2i/MECL1/b5i/LMP7/ (KO) chimera’s (fille
chimera’s (filled diamonds). Every dot represents an individual mouse, corrected for IF
(bars) ± SEM per peptide are indicated. Percentages of responding cells detected in ELISPO
experiments (n > 4 animals per group), analyzed using a two-way ANOVA with Tukey’squantified in the spleen using IFNc ICS (Fig. 3A) and IFNc ELISPOT
(Fig. 3B, Fig. S2). Confirming results from the infection studies
shown in Fig. 2B, all chimeric mice responded to the
immunoproteasome-independent E1A234-243 control epitope
(Fig. 3A), albeit some variation in responses (p < .05) was observed
using ELISPOT (Fig. 3B) but not using IFNc ICS (Fig. 3A) as read out.
As expected, the immunoproteasome-dependent E1B192-200 epi-
tope was recognized by spleen-derived CD8+ T cells of WT BM chi-
meric WT (control) recipients, while background responses
measured for KO mice reconstituted with KO BM were barely
detectable (Fig. 3A and B). In KO mice reconstituted with WT BM,
compared toWT recipients, approximately five (IFNc ICS) to seven-
fold (ELISPOT) less splenic CD8+ T cells responded to E1B192-200,d non-BM-derived cells. (A and B) Percentages of E1A or E1B-specific CD8+IFNc+ T
WT) or immunoproteasome deficient b2i/MECL1/b5i/LMP7/ (KO) bone marrow
imulation ex vivo with peptides and detection by (A) IFNc ICS using flow cytometry
BL/6 (WT) chimera’s (filled circles), b2i/MECL1/b5i/LMP7/ (KO)? B6.SJL (WT)
d triangles) and b2i/MECL1/b5i/LMP7/ (KO)? b2i/MECL1/b5i/LMP7/ (KO)
Nc background level as measured in samples incubated with medium, and means
T are shown in Supplementary Fig. 2. Data are representative of three independent
corrections (* P < .05, ** P < .01, *** P < .001, **** P < .0001).
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induce a robust E1B192-200-specific CD8+ T cell response. Unexpect-
edly, E1B192-200-specific CD8+ T cells were detected also inWTmice
reconstituted with KO BM, with percentages of responding CD8+ T
cells amounting to approximately 1%, in both assays (Fig. 3A, B).
Since the sum of both KO into WT and WT into KO approximates
the percentage of response observed in WT into WT animals, we
conclude that in DNA tattoo immunized mice, most likely, both
BM and non-BM-derived cells contribute to the processing of
pAPC-presented antigens.3.4. Langerhans cells are not responsible for dermal DNA tattoo
immunization-induced CD8+ T cell responses
LC are a radiation-resistant DC population [16] that has been
reported to contribute to antigen processing and CD8+ T cell prim-
ing [17,18]. Thus, the observed E1B192-200-specific CD8+ T cell
responses in tattoo-immunized WT recipients, reconstituted with
KO BM, may be explained by E1 antigen processing by the remain-
ing WT LC population. In order to examine the contribution of LC in
our model, WT and knock in (KI) mice expressing the diphtheria
toxin receptor (DTR) from the CD207+ promoter were reconstituted
with either WT or KO BM. Prior to and following tattoo immuniza-
tion, CD207+ DTR+ LC were ablated by i.p. injection of diphtheria
toxin (for efficiency of LC ablation, see Fig. 4A and Supplementary
Fig. 3, showing ablation in non-chimeric CD207/DTR KI mice [1]. Of
note, in the chimeric mice all CD207+ DC subsets, except for LC, are
irradiation sensitive and have been replaced by CD207+ DTR- cells
of the WT or KO BM donor at the start of the experiment). A com-
parison of E1B192-200-specific CD8+ T cell frequencies between WT
BM reconstituted CD207/DTR KI chimeras that were treated withFig. 4. LC are not responsible for the priming of CD8+ T cell response upon dermal DNA t
by a single DT injection. Depletion efficiency was measured two days later. (B and C) Fou
circles), B6.SJL (WT)? LC depleted B6.129S2-CD207tm3(DTR/GFP)Mal/J (WT) chimera’s (ope
squares) and b2i/MECL1/b5i/LMP7/ (KO)? LC depleted B6.129S2-CD207tm3(DTR/GFP)M
cells or numbers of IFNc+ cells in the spleens of mixed BM chimeric mice, immunized u
peptides and detection by (B) IFNc ICS using flow cytometry and (C) IFNc ELISPOT. (B and
measured in samples incubated with medium, and means (bars) ± SEM per peptide are
Fig. 4. Data are representative of one experiment (n = 6 animals per group), analyzed usDT and WT BM reconstituted WT control mice showed that LC
ablation enhanced rather than decreased E1B192-200-specific
responses in most mice, as measured in both IFNc ICS and ELISPOT
analysis (Fig. 4B, C, Supplementary Fig. 4). A similar pattern was
observed for E1A234-243 - specific responses in LC-ablated chimeric
mice, compared to non-ablated control groups (Fig. 4B, C). Overall,
the magnitudes of E1-specific CD8+ T cell responses detected in
this experiment were lower than in Fig. 3. Taken together, we con-
clude that in this experimental setup (Fig. 4), LC are not responsible
for the processing and priming of CD8+ T cells specific for antigens
delivered by dermal DNA tattoo immunization.4. Discussion
While accessibility and the demonstrated efficacy of cutaneous
vaccination turn the skin into an attractive barrier for vaccine
delivery, the antigen processing pathways underlying T cell prim-
ing by skin-delivered vaccines remain poorly characterized. Here
we show that following local skin immunization, both BM- and
non BM-derived cells are involved in antigen cross presentation
and priming of vaccine antigen-specific CD8+ T cells, in contrast
to systemic immunization/infection where mainly BM-derived
cells play a role. Langerhans cells were shown not to be responsible
for priming of CD8+ T cell responses upon local skin immunization.
In our study we were able to dissect different antigen process-
ing and presentation routes by exploiting an immunoproteasome-
dependent antigen in combination with BM transplanted mice, in
which either the BM donor or the recipient lacked immunoprotea-
somes, and measuring induced antigen-specific CD8+ T cell
responses. Our experiments showed that in case of systemic
rLM-E1 infection, CD8+ T cell responses to theattoo immunization. (A) LC were ablated from B6.129S2-CD207tm3(DTR/GFP)Mal/J mice
r chimeric mouse groups were made: B6.SJL (WT)? C57BL/6 (WT) chimera’s (filled
n circles) squares), b2i/MECL1/b5i/LMP7/ (KO)? B6.SJL (WT) chimera’s (filled
al/J (WT) chimera’s (open squares). Percentages of E1A or E1B-specific CD8+IFNc+ T
sing E1 cDNA tattoo immunization, were measured by re-stimulation ex vivo with
C) Every dot represents an individual mouse, corrected for IFNc background level as
indicated. Percentages of responding cells in ELISPOT are shown in Supplementary
ing a two-way ANOVA with Tukey’s corrections (* P < .05, ** P < .01, *** P < .001).
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only in mice in which BMderived cells contained immunoprotea-
somes (Fig. 2B), confirming earlier studies [14,19,20]. Thus, in Lis-
teria infection, the non-lymphoid tissues, i.e. the liver, despite
being a significant harbor of pathogen, do not serve as antigen
donor for BM-derived pAPC that prime antigen-specific CD8+ T
cells. This is in contrast to mice immunized by dermal DNA tattoo
immunization with a TTFC-E1-encoding vector, in which we mea-
sured a 50% reduction in E1B-specific responses if either donor or
recipient were deficient in immunoproteasomes (Fig. 3A, B). CD8+ T
cell activation in mice transplanted with immunoproteasome-
deficient BM could not be explained by the presence of radiation-
resistant WT LC (Fig. 4B, C), on the contrary, absence of LC seemed
to enhance the responses. These data point at a role for both BM
and non BM-derived cells in processing of DNA tattoo-delivered
vaccine antigens.
The notion that non-BM-derived cells contribute to the process-
ing of pAPC-presented antigens implies a transport of processed
peptides from these cells to DC prior to presentation. One option
for such peptide transport would be by cross-dressing, which is a
way of cross presentation [21] in which intact p-MHC-I from the
surface of a donor cell are transferred to that of an APC [22,23].
Cross dressing can take place via different ways [24], e.g. trogocy-
tosis [25], exosomes [26] or tunneling nanotubes [27]. In virus
infection, cross-dressed DC were reported to have a crucial role
in activating memory, but not naïve T cells [23]. On the contrary,
following dermal gene-gun vaccination, cross-dressed DC which
presented keratinocyte derived MHC class I – peptide complexes,
were shown to activate both naïve and memory CD8+ T cells
[28]. Since the threshold for peptide amount required for activa-
tion is higher for naïve- than memory CD8+ T cells, the observed
discrepancy between the two studies might be related to antigen
levels. These levels might be higher in local (gene gun) immuniza-
tion, resulting in effective contribution of cross dressing to the acti-
vation of naïve CD8+ T cells. Such differences in local antigen load
might also explain our observation that, in systemic infection, BM-
derived cells perform the antigen processing steps required for
CD8+ T cell priming, while the absence of immunoproteasomes in
the peripheral tissues marginally influences this process, in con-
trast to cutaneous DNA tattoo immunization where non BM-
derived cells contribute significantly.
Next to how vaccine antigens are processed and presented, the
presence of cells at the site of immunization that may either sup-
port or inhibit immune activation should be considered in vaccine
design. In our study, LC appeared to interfere with T cell activation,
in agreement to data obtained in a study by Flacher and colleagues
[29], as well as in contact hypersensitivity models [4]. Neverthe-
less, in the same models, LC also have been shown to support
CD8+ T cell priming [2,3]. The discrepancy in this seemingly con-
flicting data potentially lies in another subset of langerin-positive
DC located in the dermis, the CD11b-CD24+ dermal cDC, also called
cDC1, XCR1+ DC or Ln+ dDCs [30–32]. They are capable of present-
ing keratinocyte-dependent antigens leading to CD8+ T cell activa-
tion [30] and due to their CD207 expression, they resemble LC very
closely which might have influenced the outcome of these studies.
Thus by studying antigen processing and presentation in mice
that lack the processing machinery in specific cell subsets or miss
LC, we have provided evidence for multiple ways of cross presen-
tation upon dermal DNA tattoo immunization, with not only a role
for DCs but also for cells from the periphery. This knowledge may
be exploited to optimize vaccines that are administered in the skin.Competing financial interest
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